Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

551
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
551
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

961
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
961
Drug Therapy01:28

Drug Therapy

315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
315
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

666
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
666
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

945
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
945
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

881
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
881

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ambient black carbon and its dependence on in situ stubble burning.

Environmental monitoring and assessment·2026
Same author

ASPP-HAM-UNet: a modified UNet for moderate-to-severe traumatic brain injury segmentation.

Biomedical physics & engineering express·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

In silico and in vitro insights into stigmasterol targeting Keap1/Nrf2, Bcl-2/Bax and IKKβ/IκBα protein-protein interactions in Arsenic-induced toxicity.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Indole-3-Acetic Acid Production and Molecular Insights into its Biosynthetic Pathway.

Indian journal of microbiology·2026
Same author

Role of immunohistochemistry in differentiating between reactive and malignant lymphoid hyperplasia - A cross-sectional study.

Bioinformation·2026

Related Experiment Video

Updated: Feb 18, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Zuclopenthixol dihydrochloride for schizophrenia.

Edward J Bryan1, Marie Ann Purcell, Ajit Kumar

  • 1Sheffield Health and Social Care, NHS Foundation Trust, Fulwood House, Old Fulwood Road, Sheffield, UK, S10 3TH.

The Cochrane Database of Systematic Reviews
|November 17, 2017
PubMed
Summary

This review found limited evidence on oral zuclopenthixol dihydrochloride for schizophrenia. Due to low-quality data, firm conclusions on efficacy and side effects compared to other antipsychotics are difficult to draw.

More Related Videos

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K

Related Experiment Videos

Last Updated: Feb 18, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

12.0K
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K

Area of Science:

  • Psychiatry
  • Clinical Pharmacology
  • Evidence-Based Medicine

Background:

  • Oral zuclopenthixol dihydrochloride (Clopixol) is an antipsychotic used for schizophrenia and other psychotic disorders.
  • Potential adverse effects include neuroleptic malignant syndrome, QTc interval prolongation, extra-pyramidal reactions, and effects on glucose metabolism.

Purpose of the Study:

  • To systematically evaluate the effects of oral zuclopenthixol dihydrochloride in the treatment of schizophrenia.
  • To compare its efficacy and safety against placebo and other antipsychotic medications.

Main Methods:

  • A comprehensive search of the Cochrane Schizophrenia Group's Trials Register was conducted.
  • Included were randomized controlled trials (RCTs) with usable data on zuclopenthixol dihydrochloride for schizophrenia.
  • Data were analyzed using risk ratios and mean differences with random-effect models; risk of bias and GRADE were assessed.

Main Results:

  • Twenty trials involving 1850 participants were included, primarily short-term and inpatient data.
  • Zuclopenthixol dihydrochloride showed similar extra-pyramidal side effects (EPSEs) compared to placebo and chlorpromazine, but more than clozapine, risperidone, and perphenazine.
  • Limited data prevented firm conclusions on global state, mental state, or leaving the study early across most comparisons; short-term advantage over risperidone noted.

Conclusions:

  • The available evidence is mostly equivocal and of very low to low quality, hindering definitive conclusions.
  • Prescribing practices are unlikely to change based on this meta-analysis.
  • Further high-quality studies with broader antipsychotic comparisons are needed.